Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?

被引：6
|
作者：
Munir, Kashif M. [1 ]
Davis, Stephen N. [2 ]
机构：
[1] Univ Maryland, Sch Med, Ctr Diabet & Endocrinol, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, 22 South Greene St, Baltimore, MD 21201 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
GLP-1 receptor agonist; SGLT2; inhibitor; type; 2; diabetes; cardiovascular outcomes; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR OUTCOMES; CVD-REAL; MORTALITY; EMPAGLIFLOZIN; LIRAGLUTIDE;
D O I：
10.1080/14656566.2018.1475559
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：773 / 777
页数：5
相关论文
共 50 条
  • [41] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Suzanne V. Arnold
    Fengming Tang
    Andrew Cooper
    Hungta Chen
    Marilia B. Gomes
    Wolfgang Rathmann
    Iichiro Shimomura
    Jiten Vora
    Hirotaka Watada
    Kamlesh Khunti
    Mikhail Kosiborod
    BMC Endocrine Disorders, 22
  • [42] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [43] GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
    Scheen, Andre J.
    DRUGS, 2024, 84 (11) : 1347 - 1364
  • [44] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Lin, Donna Shu-Han
    Yu, An-Li
    Lo, Hao-Yun
    Lien, Cheng-Wei
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2022, 65 (12) : 2032 - 2043
  • [45] GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?
    Santulli, Gaetano
    Mone, Pasquale
    Varzideh, Fahimeh
    FUTURE CARDIOLOGY, 2025, 21 (01) : 5 - 8
  • [46] Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    Bonaventura, A.
    Carbone, S.
    Dixon, D. L.
    Abbate, A.
    Montecucco, F.
    JOURNAL OF INTERNAL MEDICINE, 2019, 286 (01) : 16 - 31
  • [47] Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes
    Jha, Kunal K.
    Adhikari, Rishav
    Tasdighi, Erfan
    Osuji, Ngozi
    Rajan, Tanuja
    Blaha, Michael J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 925 - 937
  • [48] The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study
    Bechlioulis, Aris
    Markozannes, Georgios
    Chionidi, Ifigeneia
    Liberopoulos, Evangelos
    Naka, Katerina K.
    Ntzani, Evangelia E.
    Liatis, Stavros
    Rizzo, Manfredi
    Rizos, Evangelos C.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (04)
  • [49] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [50] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
12345